Fig 2.

AZ5385 affects the late stage of HRV-2 life cycle. The compound at a concentration of 3.5 µM was added to HeLa cells at indicated time points relative to the beginning of virus inoculation (MOI 1) at 0 h. Two separate experiments were performed, and the data are presented as the amounts of infectious virus present in infectious medium (A) or the virus present in infectious medium (extracellular) and in infected cells (cell associated) (B) relative to the control DMSO-treated cells (24 h). Statistically significant differences ***P < 0.001.